Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119015 · ClinicalTrials.gov registry record · Phase 4
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis
A Phase 4 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
NCT00119015 is a Phase 4 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 102 participants.
The verdict
NCT00119015, a Phase 4 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
Study Summary
Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the active medication but does not contain the drug).
Interventions
- DRUG Placebo
- DRUG Montelukast
- DRUG Fluticasone propionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00119015
The ClinicalTrials.gov registry entry for NCT00119015 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00119015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00119015 about?
NCT00119015 is a clinical study titled "The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis". Some people with nasal allergy symptoms continue to have symptoms even after treatment with a nasal steroid spray. The purpose of this study is to see if these patients are helped by adding another medication (montelukast) to their treatment compared to placebo (a substance that looks like the activ...
What is the current status of trial NCT00119015?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2005-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00119015?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG), Fluticasone propionate (DRUG).
Who is sponsoring clinical trial NCT00119015?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.